Olstein Capital Management L.P. Has $6.34 Million Holdings in Ralliant Corporation $RAL

Olstein Capital Management L.P. grew its holdings in Ralliant Corporation (NYSE:RAL) by 433.8% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 145,000 shares of the company’s stock after acquiring an additional 117,834 shares during the period. Olstein Capital Management L.P.’s holdings in Ralliant were worth $6,341,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. ST Germain D J Co. Inc. acquired a new stake in Ralliant during the 2nd quarter valued at $27,000. Manchester Capital Management LLC acquired a new stake in shares of Ralliant during the 2nd quarter worth about $29,000. Evermay Wealth Management LLC acquired a new stake in shares of Ralliant during the 2nd quarter worth about $32,000. SouthState Corp bought a new stake in shares of Ralliant during the 2nd quarter worth about $35,000. Finally, EverSource Wealth Advisors LLC acquired a new position in Ralliant in the 2nd quarter valued at about $39,000.

Ralliant Price Performance

Ralliant stock opened at $51.24 on Friday. The business’s fifty day moving average is $48.48. Ralliant Corporation has a one year low of $40.70 and a one year high of $55.08. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.03 and a current ratio of 1.49. The company has a market cap of $5.78 billion and a price-to-earnings ratio of 40.34.

Ralliant (NYSE:RAL) last released its earnings results on Wednesday, November 5th. The company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.02. The company had revenue of $529.10 million for the quarter, compared to the consensus estimate of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 23rd. Shareholders of record on Monday, December 8th were paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Monday, December 8th. Ralliant’s dividend payout ratio is presently 15.75%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on RAL shares. Truist Financial began coverage on Ralliant in a research report on Friday, December 12th. They issued a “buy” rating and a $62.00 target price on the stock. Oppenheimer upped their price objective on Ralliant from $55.00 to $60.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Weiss Ratings reiterated a “hold (c)” rating on shares of Ralliant in a research report on Monday. Royal Bank Of Canada boosted their target price on shares of Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a research report on Friday, November 7th. Finally, Citigroup upgraded shares of Ralliant from a “neutral” rating to a “buy” rating and upped their price target for the company from $53.00 to $61.00 in a research note on Monday, December 8th. Six investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Ralliant has a consensus rating of “Moderate Buy” and a consensus price target of $57.89.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.